Pharmaceutical lipids market seen crossing $6.53 billion by 2030

The global pharmaceutical lipids market is projected to grow from $4.97 billion in 2026 to $6.53 billion by 2030, according to The Business Research Company. The report points to personalized medicine, lipid nanoparticles, and mRNA and biologic drug delivery as the main growth drivers.

Why it matters: - Pharmaceutical lipids are becoming more important in drug delivery because they can improve solubility, stability and bioavailability. - The market’s growth reflects broader demand for targeted therapies, injectable drugs and advanced formulations for biologics, mRNA and gene therapy. - The forecast points to expanding commercial use of lipid-based carriers in precision medicine.

What happened: - The Business Research Company released its Pharmaceutical Lipids Global Market Report 2026 – Market Size, Trends, And Forecast 2026-2035. - The report says the pharmaceutical lipids market will rise from $4.65 billion in 2025 to $4.97 billion in 2026. - The report forecasts the market will reach $6.53 billion by 2030. - The report puts the market’s CAGR at 6.8% for 2026 and 7.1% through 2030. - The report says North America led the market in 2025. - The report says Asia-Pacific is expected to be the fastest-growing region during the forecast period. - Download a free sample of the report. - View the full market report.

The details: - Pharmaceutical lipids include natural or synthetic compounds such as fatty acids, phospholipids and glycerides. - These compounds are used in lipid nanoparticles and liposomal carriers. - The report ties historical growth to natural lipid use in traditional formulations, limited bioavailability in conventional delivery systems, rising demand for injectables, higher R&D spending and the growing burden of chronic disease. - The report says future growth will be supported by lipid nanoparticle platforms for gene therapy, precision medicine-based delivery, biodegradable and sustainable lipid excipients, AI in formulation, and wider use of biologics and mRNA-based treatments. - The report highlights advances in lipid nanoparticle-mediated mRNA delivery, personalized lipid-based therapies, phospholipid excipients, sustainable lipid sourcing and targeted liposomal cancer therapies as key trends. - The report says pharmaceutical lipids support targeted drug delivery, stability and bioavailability for mRNA, siRNA and peptide drugs. - In February 2024, the Personalised Medicine Coalition said the FDA approved 16 personalized treatments for rare diseases in 2023, up from six in 2022. - The report covers Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, and the Middle East and Africa.

Between the lines: - The forecast suggests lipid delivery platforms are shifting from enabling technology to a core part of next-generation drug development. - Growth in personalized medicine and mRNA-based therapies is likely to keep pressure on drug developers to invest in more sophisticated delivery systems. - The emphasis on biodegradable and sustainable lipid excipients also signals rising attention to supply chain and environmental considerations.

What's next: - The report expects continued adoption of lipid nanoparticle platforms and personalized lipid-based drug delivery. - Wider use of biologics and mRNA therapies should keep demand elevated through 2030. - Asia-Pacific’s growth momentum may narrow the gap with North America if current trends continue. - The Business Research Company says the 2026 report package includes TAM analysis, company scoring matrix graphics, forecasting dashboards, market hotspot infographics, and updated graphics and tables.